芪苈强心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的效果及可行性分析

Effect and feasibility analysis of Qili Qiangxin capsule combined with sacubitril-valsartan sodium tablets in the treatment of chronic heart failure

目的探讨芪苈强心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的效果及可行性。方法选取2018年12月至2020年2月本院接收的100例慢性心力衰竭患者作为研究对象,根据接诊顺序按照奇偶顺序法分为常规组及研究组,各50例。常规组在常规治疗基础上联合沙库巴曲缬沙坦钠片治疗,研究组在常规组基础上联合芪苈强心胶囊治疗。比较两组临床疗效、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、N端前脑钠肽指数(NT-proBNP)]及运动耐量[6 min步行距离、动脉血氧饱和度(SaO_(2))]。结果研究组治疗总有效率为94.00%,高于常规组的78.00%,差异有统计学意义(P<0.05)。治疗后,两组LVEF高于治疗前,且研究组高于常规组,差异有统计学意义(P<0.05);两组LVEDD、LVESD、NT-proBNP均低于治疗前,且研究组低于常规组,差异有统计学意义(P<0.05)。治疗后,研究组6 min步行距离长于常规组,SaO_(2)指标高于常规组,差异有统计学意义(P<0.05)。结论芪苈强心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭效果显著,可改善患者心功能指标,促进患者恢复,值得临床推广应用。

Objective To investigate the effect and feasibility of Qili Qiangxin capsule combined with sacubitril-valsartan sodium tablets in the treatment of chronic heart failure.Methods A total of 100 patients with chronic heart failure received in our hospital from December 2018 to February 2020 were selected as the research subjects,and they were divided into routine group and study group according to the order of admissions and the odd-even method,with 50 cases in each group.The routine group was treated with sacubitril-valsartan sodium tablets on the basis of routine treatment,and the study group was treated with Qili Qiangxin capsules on the basis of routine group.The clinical efficacy and cardiac function indexes(left ventricular ejection fraction[LVEF],left ventricular end-diastolic diameter[LVEDD],left ventricular end-systolic diameter[LVESD],N-terminal pro-brain natriuretic peptide[NT-proBNP])and exercise tolerance(6 min walking distance,arterial oxygen saturation[SaO_(2)])were compared between the two groups.Results The total effective rate of the study group was 94.00%,which was higher than 78.00%of the routine group,and the difference was statistically significant(P<0.05).After treatment,the LVEF of the two groups was higher than before treatment,and the study group was higher than the routine group,the difference was statistically significant(P<0.05);the LVEDD,LVESD,NT-proBNP of the two groups were lower than those before treatment,and the study group was lower than routine group,the difference was statistically significant(P<0.05).After treatment,the 6 min walking distance in the study group was longer than that in the routine group,and the SaO_(2) index was higher than that in the routine group,and the difference was statistically significant(P<0.05).Conclusion The Qili Qiangxin capsules and sacubitril-valsartan sodium tablets in the treatment of patients with chronic heart failure has significant effect,can improve the cardiac function indexes of patients,and promote the recovery of patients,which is worthy of clinical application.